Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty.
Publication/Presentation Date
6-1-1999
Abstract
The use of abciximab after full-dose failed thrombolytics within 15 hours of acute myocardial infarction significantly increases the risk of major bleeding complications.
Volume
83
Issue
11
First Page
1569
Last Page
1571
ISSN
0002-9149
Published In/Presented At
Sundlof, D. W., Rerkpattanapitat, P., Wongpraparut, N., Pathi, P., Kotler, M. N., Jacobs, L. E., Ledley, G. S., & Yazdanfar, S. (1999). Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty. The American journal of cardiology, 83(11), 1569–A7. https://doi.org/10.1016/s0002-9149(99)00151-4
Disciplines
Medicine and Health Sciences
PubMedID
10363875
Department(s)
Department of Medicine, Cardiology Division
Document Type
Article
COinS